RxDoctor Payments DataLook up a doctor →

Liliana Montoya, MD

Neurology · Port Charlotte, FLNPI 1245255793

Payments from drug & device makers

$3,404,460in general payments, 2019–2025

Across 906 payments — averaging $3757.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2.5M
  • Eisai Inc.$310K
  • Adamas Pharmaceuticals, Inc.$294K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$83K
  • Regeneron$76K
  • EMD Serono, Inc.$64K
  • plus $123K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis77$2,454,215
Eisai Inc.152$309,727
Adamas Pharmaceuticals, Inc.57$294,117
Otsuka Pharmaceutical Development & Commercialization, Inc.7$83,324
Regeneron116$76,314
EMD Serono, Inc.66$63,826
Bristol Myers Squibb9$28,008
Roche Products Limited39$24,286
Biogen44$22,595
Jazz Pharmaceuticals Inc.7$15,489
Genentech, Inc.4$12,103
Sanofi16$7,617
H. Lundbeck A S2$4,115
E.r. Squibb & Sons, L.L.C.5$1,612
AbbVie(2 entities)62$1,046
Ares Trading SA7$595
Lilly USA, LLC26$582
Amgen30$497
UCB, Inc.18$367
Amneal Pharmaceuticals LLC13$360
Teva Pharmaceuticals USA, Inc.16$295
Johnson & Johnson(2 entities)9$281
Neurocrine Biosciences, Inc.7$263
Pfizer10$226
Abbott4$217
Otsuka America Pharmaceutical, Inc.9$203
Merz North America, Inc.4$179
Mallinckrodt Hospital Products Inc.6$160
Acadia Pharmaceuticals Inc7$145
Acorda Therapeutics, Inc6$131
Lundbeck LLC6$115
Argenx US, Inc.4$114
Avion Pharmaceuticals5$108
Genentech USA, Inc.5$108
SK Life Science, Inc.4$104
Alnylam Pharmaceuticals Inc.5$95
Catalyst Pharmaceuticals, Inc.2$79
Biohaven Pharmaceuticals, Inc.2$59
AstraZeneca3$59
Tanabe Pharma America, Inc.2$58
Biohaven Pharmaceutical Holding Company Ltd.2$56
Azurity Pharmaceuticals, Inc.3$53
Vanda Pharmaceuticals Inc.2$50
Scilex Pharmaceuticals Inc.2$44
Livanova USA, Inc.2$41
Saol Therapeutics Inc.2$40
Kyowa Kirin, Inc.2$39
MDD US Operations, LLC2$31
GE HealthCare2$30
TG Therapeutics, Inc.1$29
Almatica Pharma LLC1$29
Upsher-smith Laboratories LLC1$23
Sanofi-aventis U.S. LLC1$23
CSL Behring1$22
Octapharma USA, Inc.1$21
C2n Diagnostics, LLC1$21
Cycle Pharmaceuticals Inc1$19
Corium, LLC1$18
Neurelis, Inc.1$17
Life Molecular Imaging Ltd1$17

How this compares

$3,404,460 in reported general payments places this provider in the 95th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida →

Medicare billing

Part B allowed, 2024
$378,131
Medicare patients
850
Services billed
19,664

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Port Charlotte

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →